Santen Pharmaceutical-Un ADRSNPHY
13F holders, Q3 2025 (September 30)2holders
0new positions
0sold out
$11.27avg. 13F price*
At the end of Q3 2025, 2 institutions reported holding Santen Pharmaceutical-Un ADR (SNPHY) in their 13F filings, unchanged from Q2 2025. 0 opened new positions and 0 sold out. The largest holders were Rhumbline Advisers ($13K) and Copeland Capital Management, LLC ($3K).
- Company
- Santen Pharmaceutical-Un ADR
- CUSIP
- 80287P100
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q2 2025 → Q3 2025: 1,167 shares bought, net +1,167 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Rhumbline Advisers | 0.00% | Add +3890.0% | 1,197 | $13K |
| Copeland Capital Management, LLC | 0.00% | No change | 286 | $3K |
"% of holder's portfolio" is SNPHY's weight in each manager's 13F, not the share of Santen Pharmaceutical-Un ADR the manager owns.